A decision analysis model focusing on hospitalisation, survival rates and utilities for paricalcitol and calcitriol was used (Figure 1). Costs included yearly cost for medications and the costs ...
The incremental number of hospitalisation admissions per year was 0.846 fewer for patients who started and remained on intravenous paricalcitol than for patients being treated with calcitriol.
Cancer prevention is currently envisioned as a molecular-based approach to prevent carcinogenesis in pre-cancerous stages, i.e., dysplasia and carcinoma in situ. Cancer is the second-leading cause of ...